What’s Going On With Acurx Pharmaceuticals Stock Now?

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares are blasting higher Thursday and have gained more than 300% over the last five days.

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares are blasting higher Thursday and have gained more than 300% over the last five days.

What To Know:

Shares of ACXP are up on extremely heavy trading volume Thursday with more than 5.7 million shares already traded in the session.

According to data from Benzinga Pro, the stock’s 100-day average trading volume is less than 355 thousand shares. 

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

The company announced positive results from a Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for the treatment of patients with Clostridioides difficile infection on Oct. 2. 

Acurx Pharmaceuticals’ stock has a 50-day moving average of $1.86 and a 52-week range of $1.17 to $4.61. 

Related News: What’s Going On With Jaguar Health Stock? 

ACXP Price Action: According to Benzinga Pro, Acurx Pharmaceuticals shares are up 64% at $6.14 at the time of publication.

Image: Miguel Á. Padriñán from Pixabay

Total
0
Shares
Related Posts
Read More

Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study

Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the company has decided not to 

KRON